The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM
Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses her recent study on the use of mass spectrometry (MS) in patients with high-risk smoldering myeloma (HR-SMM), focusing on its prognostic value compared to standard methods like serum protein electrophoresis and immunofixation. While standard methods lacked clinical value, MS and next-generation flow (NGF) identified groups with distinct prognoses, especially when tracking measurable residual disease (MRD) over time. Patients exhibiting persistent MRD-negativity showed favorable outcomes, while those remaining MRD-positive had poorer progression-free survival (PFS). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
